Attention FSD Pharma Shareholders the Future of your Investment is at a stake

After a review of the facts, the best – and only – way to protect Shareholder interests and to support value creation is to vote FOR all Management Director Nominees and resolutions using only the BLUE proxy.

Read More

Vote using the BLUE Proxy for the Right Strategy, stronger Shareholder Democracy and the Right Board of Directors

Your Board and Management team’s current strategy continues to build positive momentum and offers a number of avenues to significant value creation for ALL Shareholders.

Read More

Protect your Investment WITHHOLD from voting for ANY of the Dissident Director Nominees

Your Company has put forward five seasoned and two new Management Director Nominees for election to the Board who all have the requisite skills, experience and track records to represent the interests of ALL Shareholders.

Read More

Vote FOR the Management Director Nominees and Resolutions on the BLUE Proxy Today

Time is of the essence. To ensure that your vote is counted at the Meeting please vote immediately and no later than 9:00 a.m. (Toronto/New York time) on May 12, 2021.

Vote Blue Now

The Dissidents in their information circular have not shared a new, superior, detailed strategic or value creating plan for the Shareholders nor have they provided credentials of a qualified management team.

Reasons to support

The future of your investment is at stake. Please vote only the BLUE proxy FOR all proposed resolutions contained in the management information circular at the annual and special meeting of the shareholders on May 14, 2021.

This proxy contest is about Anthony Durkacz, Zeeshan Saeed and the other dissident shareholders' self-serving plan to have FSD Pharma Inc. acquire a start-up notionally in the psychedelics sector, with no track record, cash, or research and development activities, and the failure of Mr. Durkacz and certain other Dissidents, to properly disclose their substantial interests in the Start-Up. The Dissidents in their information circular have not shared a new, superior, detailed strategic or value creating plan for the Shareholders nor have they provided credentials of a qualified management team. That is because they do not have one.

Learn More

The Right Board

The proxy contest offers Shareholders a choice between a professional slate of Management Director Nominees and a slate of Dissident Director Nominees with minimal experience and questionable interlocking relationships. The Company has put forward seven Management Director Nominees who all have the requisite skills, experience and track records to represent the interests of ALL Shareholders.

The incumbent Management Director Nominees are directly responsible for the Company's turnaround from a failed cannabis start-up to a well-capitalized, advanced drug development company. They have the skills and experience to advance the FDA trials and pursue further drug development opportunities.

Read More

Increase the value of your investment.

Vote Blue Now
Fill out my online form.

Speak to a Live Agent

Send us your questions, comments, and/or feedback and we will get back to you as soon as we can.

Name:

Email:

Comments: